No Data
Traws Pharma Announces Results From Study of Tivoxavir Marboxil in Bird Flu
Traws Reports Topline Results From Study Evaluating The Use Of Tivoxavir Marboxil As Treatment For Non-human Primates Challenged With Non-lethal Dose Of H5N1 Bird Flu; Results Build On Earlier Findings Of Mortality Benefit For TXM In Ferrets And Mice
Express News | Traws Pharma Inc - FDA Briefing Documents in Preparation for Discussion of Potential Accelerated Path to Approval
Express News | Traws Pharma Inc - Presents Positive Data for Txm as Bird Flu Treatment at Icar
Express News | Traws Pharma Inc - Enters $50 Million Atm Agreement With Citizens Jmp Securities
Express News | Traws Pharma Shares Are Trading Lower. The Company Announced Topline Results From Ferrets Infected With H5N1 Bird Flu
